JCS Analytics - We are analysts. We Ask. We Automate. We Discover.

Abstract

Lundbeck’s AI Days offers a practical example of how organizations can approach AI adoption as a structured capability-building effort rather than a simple technology rollout. By connecting AI to business strategy, involving senior leadership, offering hands-on training, and emphasizing responsible use, Lundbeck shows how companies can help employees build confidence while aligning AI experimentation with clear organizational goals. For data and analytics teams, the example reinforces an important point: AI works best when it builds on strong data foundations, clear workflows, sound governance, and measurable business value.

Key Points

• AI adoption should connect directly to business strategy, not sit apart as a disconnected technology initiative.
• Leadership involvement helps set expectations and gives employees permission to learn, experiment, and rethink workflows.
• Hands-on training matters more than hype because employees need practical examples tied to real work.
• Governance should be built in from the start, including approved tools, data handling rules, human review, and validation standards.
• Data and analytics teams play an important role because AI depends on clean data, clear processes, strong documentation, and measurable outcomes.

Abstract

This post explores how visualizing continuous glucose monitor (CGM) data by hour—rather than by day—reveals deeper insights into when glucose levels shift. By replacing traditional Time in Range charts with dynamic, time-specific visualizations, this approach emphasizes understanding over judgment. It highlights patterns like post-meal spikes and overnight stability, making glucose data more actionable and emotionally neutral.

Key Points

• Hourly View Adds Context: Reveals when glucose levels go out of range, not just how often.
• Flexible Range Selection: Users can toggle between 70–180 mg/dL and 70–140 mg/dL thresholds.
• Reframed Visual Cues: Reversed green-blue color scale avoids framing results as good or bad.
• Actionable Patterns: Shows consistent overnight control and post-meal variability.
• Emphasis on Exploration: Focuses on patterns and possibilities, not compliance.
• Technical Approach: Uses Tableau calculated fields for hourly binning and dynamic formatting.

Abstract

Eli Lilly has introduced TuneLab, an AI platform that provides biotech companies access to drug discovery models trained on more than $1 billion of proprietary research data. The platform uses federated learning to let partners apply and improve these models without exchanging raw datasets. At the same time, Lilly is building one of the most powerful AI supercomputers in the pharmaceutical industry to support large-scale model development. Together, these moves represent a shift toward AI-augmented scientific workflows, where data, compute, and collaboration accelerate early-stage drug discovery.

Key Points

• TuneLab provides access to high-value drug discovery models trained on decades of internal R&D data.
• Federated learning protects proprietary data, allowing partners to use and strengthen models without sharing raw files.
• A large-scale NVIDIA-powered supercomputer supports model training, simulation, and scientific AI agents.
• The initiative lowers barriers for early-stage biotechs, offering capabilities that previously required significant infrastructure.
• The broader shift is toward AI-augmented research, where discovery speed depends on both scientific insight and computational scale.